Alaunos Therapeutics (TCRT) Projected to Post Quarterly Earnings on Tuesday

Alaunos Therapeutics (NASDAQ:TCRT) is expected to issue its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect Alaunos Therapeutics to post earnings of ($3.6858) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, April 2, 2026 at 4:00 PM ET.

Alaunos Therapeutics Stock Up 6.2%

Shares of NASDAQ:TCRT opened at $3.61 on Monday. The firm has a fifty day simple moving average of $2.94 and a two-hundred day simple moving average of $2.93. Alaunos Therapeutics has a 52 week low of $1.31 and a 52 week high of $6.20. The stock has a market capitalization of $8.38 million, a P/E ratio of -1.56 and a beta of -1.29.

Institutional Trading of Alaunos Therapeutics

An institutional investor recently bought a new position in Alaunos Therapeutics stock. HRT Financial LP acquired a new position in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 12,602 shares of the company’s stock, valued at approximately $40,000. HRT Financial LP owned 0.54% of Alaunos Therapeutics as of its most recent SEC filing. 27.72% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alaunos Therapeutics in a report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Alaunos Therapeutics has an average rating of “Sell”.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.